QuiaPEG Pharmaceuticals Holding AB
Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as… Read more
QuiaPEG Pharmaceuticals Holding AB (QUIA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.115x
Based on the latest financial reports, QuiaPEG Pharmaceuticals Holding AB (QUIA) has a cash flow conversion efficiency ratio of -0.115x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-747.00K) by net assets (Skr6.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
QuiaPEG Pharmaceuticals Holding AB - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how QuiaPEG Pharmaceuticals Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
QuiaPEG Pharmaceuticals Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of QuiaPEG Pharmaceuticals Holding AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Point of Care Nano-Technology Inc
PINK:PCNT
|
0.008x |
|
DALATA HOTEL (DHG.SG)
STU:DHG
|
N/A |
|
176750
KO:176750
|
N/A |
|
JOST (JOX.SG)
STU:JOX
|
N/A |
|
Blackrock Innovation & Growth Trust
NYSE:BIGZ
|
N/A |
|
XMax Inc.
NASDAQ:XWIN
|
-0.140x |
|
StageZero Life Sciences Ltd
PINK:SZLSF
|
-0.001x |
|
KARO INVEST a.s.
PR:KARIN
|
N/A |
Annual Cash Flow Conversion Efficiency for QuiaPEG Pharmaceuticals Holding AB (2008–2024)
The table below shows the annual cash flow conversion efficiency of QuiaPEG Pharmaceuticals Holding AB from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr16.35 Million | Skr-10.17 Million | -0.622x | +7.61% |
| 2023-12-31 | Skr15.25 Million | Skr-10.27 Million | -0.673x | +91.07% |
| 2022-12-31 | Skr2.41 Million | Skr-18.18 Million | -7.536x | +99.18% |
| 2021-12-31 | Skr22.00K | Skr-20.11 Million | -914.091x | -129.27% |
| 2020-12-31 | Skr71.00K | Skr-28.31 Million | -398.704x | -22715.75% |
| 2019-12-31 | Skr-8.57 Million | Skr-15.11 Million | 1.763x | +109.25% |
| 2018-12-31 | Skr545.00K | Skr-10.39 Million | -19.068x | -1007.89% |
| 2017-12-31 | Skr6.04 Million | Skr-10.39 Million | -1.721x | -1865.23% |
| 2016-12-31 | Skr18.44 Million | Skr1.80 Million | 0.098x | +38.56% |
| 2015-12-31 | Skr6.92 Million | Skr487.00K | 0.070x | -69.52% |
| 2014-12-31 | Skr6.44 Million | Skr1.49 Million | 0.231x | -24.20% |
| 2013-12-31 | Skr7.24 Million | Skr2.21 Million | 0.305x | +156.89% |
| 2012-12-31 | Skr9.73 Million | Skr-5.21 Million | -0.535x | -393.31% |
| 2011-12-31 | Skr13.98 Million | Skr2.55 Million | 0.183x | +18.41% |
| 2010-12-31 | Skr17.17 Million | Skr2.65 Million | 0.154x | +50.57% |
| 2009-12-31 | Skr17.82 Million | Skr1.82 Million | 0.102x | +92.50% |
| 2008-12-31 | Skr17.98 Million | Skr956.00K | 0.053x | -- |